Losipaco 12 Compresse 2mg+125mg


SKU: cd4d7c7e08d9 Category:


Description Losipaco 12 tablets 2mg + 125mglosipaco 12 tablets 2mg + 125mg
Pharmacotherapeutic category: anti-narrownive antipropulsives.
Active principles: Each tablet contains 2 mg of loperamide hydrochloride and simeticone equivalent at 125 mg of dampeticone. Excipients: Microcrystalline Cellulose (E460), Sodium Glycolato Amido, Ipromellosa (E464), Povidone (E2101), Football Phosphate (E341), Mannitolo (E421), Mag Nesio Stearato (E572).
Indications: Symptomatic treatment of acute diarrhea in adults and adols scents of age equal to 12 years when acute diarrhea is associated with abdominal disturbance related to meteorism, including swollen kings, cramps or flatulence.
Contraindications / Eff.Secondar: not used in children of age less than 12 years; In patients with ipe rsensibilita ‘note (allergy) to loperamide hydrochloride, at simeticone or to any of the excipients; In patients with acute dysentery, which is characterized by blood in the stool and high fever; In patients with acute ulcerative colitis; In patients with pseudomembranous colitis to ssociata to the use of broad spectrum antibiotics; In patients with bacterial enter enter caused by invasive organisms included Salmonella, SH Igella and Campylobacter Losipaco tablets should not be used when it is necessary to avoid the peristali inhibition due to a positive risk of significant seizures including Ileo, Megacolon, Megac Olon toxic. The therapy must be immediately interrupted when constipation, ileo or when Development of Male Pale is developed.
Posology: The tablets must be taken with liquid. Adults over 18 years: two tablets to be taken initially, followed by a Mpressa coat after each diarrheal discharge. No more than 4 tablets are not taken in a day, limited to no more than 2 days. TOLETS NTI BETWEEN 12 AND 18 YEARS: a tablet to be taken initially, followed by a tablet after each diarrheal discharge. You don’t have to take P IU ‘of 4 tablets in a day, limited to no more than 2 days. Use in children: the tablets should not be used in children under the age of 12. Use in elderly patients: no dosage adjustment is needed for elderly patients. Use in the renal comprom: In case of renal impairment, an adjustment of the dosage is not required. Use in hepatic impairment: Bench is not available pharmacokinetic data in patients with hepatic sparkfield, the medicine must be used with caution in ques you patients due to a reduced first passage metabolism.
Storage: This medicine does not require any particular condition of conserving vation.
Warnings: The treatment of diarrhea with Loperamide-Simeticone is only tico symptom. If appropriate, specific treatment must be administered whenever a basic etiology can be determined. In patients with diarrhea (severe) it can occur hydrolypholic depletion. It is important to pay attention to an adequate restoration of liquids and electrolytes. If no CLI NICO improvement is observed within 48 hours, administration must be interrupted. CiSi NTI must be advised to consult your doctor. Patients with AIDS treated with Lospaco tablets for diarrhea must interromper and therapy to the first signs of abdominal distension. RiFe rites are isolated cases of constipation with an increase in the risk of megacol on toxic in patients with AIDS with infectious colitis by pathogens both b ancher or viral treated with loperamide hydrochloride. Although pharmacokinetic data is not available in patients with hepatic impairment, the medicine must be used with caution in these patients because of a reduced first passage metabolism. This nale doctors must be used with caution in patients with EPAT ICA impairment ‘can cause relative overdose that leads to a tobug to be paid by the central nervous system (SNC). In patients with severe lospaco lease dysfunction tablets should be used under medical uPrevision. Interactions: non-clinical data showed that loperamide is a substrate of glycoprotein p. the concomitant administration of loperamide (16 mg in single dose) with quinidine or ritonavir, both glycoprotein p inhibitors, they caused an increase of 2-3 times of the Plasma concentrians of Loperamide. The clinical relevance of this pharmacokinetic action with Glycoprotein P inhibitors, when Loperamide is administered to recommended dosages, is not known. Concomitant administration of Loperamide (4 mg in single dose) and traconazole, a CYP3A4 and glycoprotein p inhibitor, increased plasma loperamide concentrations of 3-4 times. In the same s tudio, gemfibrozil, a CYP2C8 inhibitor, has increased the loperamide of about 2 times. Concomitant use of Itraconazole and Gemfibrozil has increased the maximum plasma levels of Loperamide of 4 times and and total plasma spy 13 times. This increase has not been associated with measurable effects on the SNC, as measured with Psychom-oriented tests (eg subjective drowsiness and replacement testing tests / simb oils – Digit Symbol Substitution test). The concomitant and loperamide administration (16 mg in single dose) and chetoconazole, a CYP3A4 and glycoprotein p inhibitor, gave rise to a 5-time increase of l operamide plasma concentrations. This increase is not associated with increased pharmacodynamic effects as measured by P Upillometry. Concomitant treatment with desmopressin for submin oral design has caused a 3-time increase of plasma desmopressin concentrations, presumably due to slow-backed gast. It is expected that medicines with similar drugs can enhance the effect of loperamide and that the medicines that accelerate gastrointestinal transit can reduce and effects. Simeticone is not absorbed by the Ointestinal GASTR section, relevant interactions between simeticone and other medicines are not expected.
Unwanted effects: adverse drug reactions to the most frequently reported drug are Stat and Nausea and Dispeusia. Frequencies Adverse reactions: very common (> = 1/10), Municipality (> = 1/100, <1/10), uncommon (> = 1/1000, <1/100), rare (> = 1/1 0.000, <1/1000), very rare (<1 / 10,000), not known. Immune system disorders. Not note: hypersensitivity included anaphylactic shock, anaphylactoid reaction. Nervous system pathologies. Uncommon: Son Nighthess, not note: Loss of consciousness, depressed level of consciousness, dizziness. Gastrointestinal pathologies. Municipality: Nausea, Dispeusia; uncommon. constipation; Not note: Megacolon, including toxic megacolon; Ileo; abdominal pain; He retched; abdominal distension; dyspepsia; Flatul Enza. Cute and subcutaneous tissue pathologies. Uncommon: skin eruption; Not known: Angioedema, urticaria, itching. Ren wings and urinary pathologies. Not note: urinary retention. Report any suspicious adverse reaction through the national reporting system. Pregnancy and breast-feeding: limited data are available on the use of loperamide in women in g Ravidance. In one of two epidemiological studies the use of Loperamide lasts the first phase of the pregnancy has suggested a possible éded increase in the risk of hypospadia, however it was not possible to focus an increase in the risk of major malformations. Nimali studies do not indicate direct or indirect effects related to reproductive toxicity. If possible, the use of loperamide must and shares avoided during the first trimester of pregnancy, however it can be used during the second and third trimester of pregnancy. Only small quantities of loperamide hydrochloride can appear in breast milk. Therefore, Losipaco can be used during breastfeeding when dietary measures are insufficient and a drug-induced inhibition of intestinal motion is indicated. Only elevated doses and loperamide hydrochloride have influenced female fertility the n non-clinical studies.